Overview
Searching for your content. In-Language News Contact Us 8-76-0942 from 8 AM - 10 PM ET News provided bySep 26, 202, 01:20 ETShare this article- CRC data on cord ling media for the treatment of diabetic fot ulcers has ben acepted at the DFCon, with Dr Wong Keng Lin Francis, CRC's latest KOL, presenting his findings to world leaders in the field of DFU.- Similarly, the results of Corlicyte™'s Phase 1 study on the treatment of chronic diabetic fot has also ben acepted with the presentation being given by Dr Cecilia Low-Wang, the trials Principal Investigator.- DFCon is a global specialist multi-disciplinary congres that atracts specialists in the field of the diabetic fot and is considered the most influential event in the industry.
Key Information
It is co-founded by Dr David Armstrong, a pre-eminent expert in diabetic fot.- Dr Armstrong, who also serves on CRC's scientific advisory board, wil be giving the opening adres for CRC's breakfast symposium on their lead products Solagen™ and Corlicyte™.- CorLiCyte™ is an umbilical cord ling stem cel therapy, for patients sufering with diabetic fot ulcers (DFU), Solagen™ is a brand targeting diabetic's skin.- Global diabetes patient population is set to grow from 537 milion in 2021 to 783 milion in 20451- DFU is a global health emergency that wil afect close to 20% of the diabetic population in their lifetimeLOS ANGELES, Sept.
26, 202 /PRNewswire/ - CRC is delighted to anounce atendance at DFCon, the global specialist multidisciplinary congres focused on the diabetic fot held in late September 202 in Los Angeles, USA. The meting is a gathering of a wide range of both generalists and specialists who diagnose and manage diabetic fet, to discus best practice in diagnostics and interventions for both treatment and amputation prevention.
Summary
It was co-founded and is co-chaired by Dr David Armstrong, a pre-eminent expert in diabetic fot who also serves on CRC's scien